|
FDA Acknowledges Caving to Influence Peddling--ReGen / ECT |
|
|
|
Wednesday, 14 October 2009 |
|
Dr. Joshua Sharfstein, the FDA's principal deputy commissioner,
acknowledged: “The message here is that there were problems with the
integrity of F.D.A.’s decision-making process that have solutions.”
|
|
Read more...
|
|
|
Top FDA Officials, Compromised by Conflicts of Interest |
|
|
|
Tuesday, 18 August 2009 |
Two high ranking FDA officials' conflicts of interest have led one to
resign, the other is under investigation by the Inspector General of
the Department of Health and Human Services:
|
|
Read more...
|
|
|
Conflicts for FDA committee set to weigh risks of Seroquel_Philadelphia Inquirer |
|
|
|
Saturday, 04 April 2009 |
|
FDA officials who continue to run its powerful center for drug evaluation (CDER) have once again shown bad faith by appointing financially compromised doctors to the Psychopharmacologic Drugs
Advisory Committee (PDAC) advisory panel.
|
|
Read more...
|
|
|
Obama's Health Plan Could be Hijacked by Industry Which Sees Good Business |
|
|
|
Thursday, 05 March 2009 |
|
The Washington Post suggests, the chance for success in overhauling US healthcare depends on President Obama's ability to keep the major--discordant--players on board. |
|
Read more...
|
|
|
Letter of Complaint Re: FDA Double Agent |
|
|
|
Sunday, 27 April 2008 |
|
A follow-up letter to FDA Commissioner, Andrew vonEschenbach RE: Thomas Laughren, FDA's 's Director of Psychiatry Products who has been actively promoting psychotropic drugs--even penning his name to ghostwritten industry-sponsored articles and consensus panels.
|
|
Read more...
|
|
|
|
<< Start < Prev 1 2 3 Next > End >>
|
| Results 1 - 9 of 22 |
